Immunocore Holdings plc Logo

Immunocore Holdings plc

IMCR

(1.0)
Stock Price

31,59 USD

-5.88% ROA

-16.68% ROE

-25.42x PER

Market Cap.

1.529.038.215,00 USD

122.38% DER

0% Yield

-19.15% NPM

Immunocore Holdings plc Stock Analysis

Immunocore Holdings plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Immunocore Holdings plc Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (24%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 ROE

Negative ROE (-17.69%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-11.31%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (6.62x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-21.180) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Immunocore Holdings plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Immunocore Holdings plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Immunocore Holdings plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Immunocore Holdings plc Revenue
Year Revenue Growth
2018 23.654.000
2019 25.669.000 7.85%
2020 30.114.000 14.76%
2021 26.520.000 -13.55%
2022 143.737.000 81.55%
2023 205.952.000 30.21%
2023 249.428.000 17.43%
2024 301.600.000 17.3%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Immunocore Holdings plc Research and Development Expenses
Year Research and Development Expenses Growth
2018 83.575.000
2019 99.991.000 16.42%
2020 74.809.000 -33.66%
2021 73.226.000 -2.16%
2022 89.170.000 17.88%
2023 126.716.000 29.63%
2023 163.545.000 22.52%
2024 204.288.000 19.94%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Immunocore Holdings plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2018 34.156.000
2019 44.183.000 22.69%
2020 45.740.000 3.4%
2021 88.399.000 48.26%
2022 0 0%
2023 43.960.000 100%
2023 0 0%
2024 102.348.000 100%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Immunocore Holdings plc EBITDA
Year EBITDA Growth
2018 -80.947.000
2019 -107.714.000 24.85%
2020 -75.447.000 -42.77%
2021 -135.115.000 44.16%
2022 -36.453.000 -270.66%
2023 56.232.000 164.83%
2023 -38.470.000 246.17%
2024 -19.464.000 -97.65%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Immunocore Holdings plc Gross Profit
Year Gross Profit Growth
2018 23.654.000
2019 -74.322.000 131.83%
2020 -44.695.000 -66.29%
2021 -46.706.000 4.31%
2022 143.283.000 132.6%
2023 205.072.000 30.13%
2023 248.391.000 17.44%
2024 294.772.000 15.73%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Immunocore Holdings plc Net Profit
Year Net Profit Growth
2018 -71.630.000
2019 -103.931.000 31.08%
2020 -74.093.000 -40.27%
2021 -131.523.000 43.67%
2022 -41.224.000 -219.04%
2023 7.616.000 641.28%
2023 -55.287.000 113.78%
2024 -46.464.000 -18.99%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Immunocore Holdings plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2018 -3
2019 -4 33.33%
2020 -2 -50%
2021 -3 33.33%
2022 -1 0%
2023 0 0%
2023 -1 100%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Immunocore Holdings plc Free Cashflow
Year Free Cashflow Growth
2018 -20.163.000
2019 -105.652.000 80.92%
2020 -63.648.000 -65.99%
2021 -130.757.000 51.32%
2022 -33.466.000 -290.72%
2023 3.402.000 1083.72%
2023 -2.485.000 236.9%
2024 23.141.000 110.74%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Immunocore Holdings plc Operating Cashflow
Year Operating Cashflow Growth
2018 -16.626.000
2019 -101.376.000 83.6%
2020 -60.574.000 -67.36%
2021 -129.749.000 53.31%
2022 -31.269.000 -314.94%
2023 5.118.000 710.96%
2023 2.940.000 -74.08%
2024 23.472.000 87.47%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Immunocore Holdings plc Capital Expenditure
Year Capital Expenditure Growth
2018 3.537.000
2019 4.276.000 17.28%
2020 3.074.000 -39.1%
2021 1.008.000 -204.96%
2022 2.197.000 54.12%
2023 1.716.000 -28.03%
2023 5.425.000 68.37%
2024 331.000 -1538.97%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Immunocore Holdings plc Equity
Year Equity Growth
2018 56.582.000
2019 14.771.000 -283.06%
2020 55.346.000 73.31%
2021 171.547.000 67.74%
2022 278.756.000 38.46%
2023 368.843.000 24.42%
2023 291.543.000 -26.51%
2024 359.136.999 18.82%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Immunocore Holdings plc Assets
Year Assets Growth
2018 195.777.000
2019 185.649.000 -5.46%
2020 197.194.000 5.85%
2021 301.773.000 34.65%
2022 435.518.000 30.71%
2023 597.001.000 27.05%
2023 464.119.000 -28.63%
2024 1.023.365.000 54.65%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Immunocore Holdings plc Liabilities
Year Liabilities Growth
2018 139.195.000
2019 170.878.000 18.54%
2020 141.848.000 -20.47%
2021 130.226.000 -8.92%
2022 156.762.000 16.93%
2023 228.158.000 31.29%
2023 172.576.000 -32.21%
2024 664.228.000 74.02%

Immunocore Holdings plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.28
Net Income per Share
-1.2
Price to Earning Ratio
-25.42x
Price To Sales Ratio
4.87x
POCF Ratio
107.17
PFCF Ratio
141.28
Price to Book Ratio
4.26
EV to Sales
4.77
EV Over EBITDA
-62.56
EV to Operating CashFlow
104.93
EV to FreeCashFlow
138.32
Earnings Yield
-0.04
FreeCashFlow Yield
0.01
Market Cap
1,53 Bil.
Enterprise Value
1,50 Bil.
Graham Number
13.94
Graham NetNet
4.84

Income Statement Metrics

Net Income per Share
-1.2
Income Quality
-0.21
ROE
-0.17
Return On Assets
-0.06
Return On Capital Employed
-0.08
Net Income per EBT
0.94
EBT Per Ebit
0.93
Ebit per Revenue
-0.22
Effective Tax Rate
0.06

Margins

Sales, General, & Administrative to Revenue
0.27
Research & Developement to Revenue
0.71
Stock Based Compensation to Revenue
0.14
Gross Profit Margin
0.99
Operating Profit Margin
-0.22
Pretax Profit Margin
-0.2
Net Profit Margin
-0.19

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.29
Free CashFlow per Share
0.22
Capex to Operating CashFlow
0.24
Capex to Revenue
0.01
Capex to Depreciation
0.9
Return on Invested Capital
-0.08
Return on Tangible Assets
-0.06
Days Sales Outstanding
69.99
Days Payables Outstanding
3689.05
Days of Inventory on Hand
640.27
Receivables Turnover
5.21
Payables Turnover
0.1
Inventory Turnover
0.57
Capex per Share
0.07

Balance Sheet

Cash per Share
17,19
Book Value per Share
7,18
Tangible Book Value per Share
7.18
Shareholders Equity per Share
7.18
Interest Debt per Share
8.97
Debt to Equity
1.22
Debt to Assets
0.43
Net Debt to EBITDA
1.34
Current Ratio
5.17
Tangible Asset Value
0,36 Bil.
Net Current Asset Value
0,29 Bil.
Invested Capital
811882000
Working Capital
0,77 Bil.
Intangibles to Total Assets
0
Average Receivables
0,06 Bil.
Average Payables
0,02 Bil.
Average Inventory
3814500
Debt to Market Cap
0.29

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Immunocore Holdings plc Dividends
Year Dividends Growth

Immunocore Holdings plc Profile

About Immunocore Holdings plc

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

CEO
Dr. Bahija Jallal Ph.D.
Employee
497
Address
92 Park Drive
Abingdon, OX14 4RY

Immunocore Holdings plc Executives & BODs

Immunocore Holdings plc Executives & BODs
# Name Age
1 Ms. Lily Margaret Hepworth
Senior Vice President, General Counsel & Company Secretary
70
2 Dr. Bahija Jallal Ph.D.
Chief Executive Officer & Executive Director
70
3 Mr. Brian R. Di Donato M.B.A.
Executive Vice President, Chief Financial Officer & Strategy
70
4 Ms. Tina St. Leger
Chief Human Resources Officer
70
5 Dr. David Berman M.D., Ph.D.
Executive Vice President of Research & Development
70
6 Mr. John Trainer M.B.A.
SVice President & Chief Operating Officer
70
7 Mr. John Goll III
SVice President, Finance & Chief Accounting Officer
70
8 Ms. Annelise Vuidepot Ph.D.
Senior Vice President, Chief Technology Officer and Research & UK Site Lead
70
9 Mr. Sean D. Buckley
Vice President & Chief Information Officer
70
10 Clayton Robertson
Head of Investor Relations
70

Immunocore Holdings plc Competitors